WIPO side event, December 6, 2018, on the Implications of Article 27.3(a) of the WTO TRIPS Agreement on the patentability of gene and cell-based therapies

DATE: Thursday, 6 December 2018
TIME: 1:30 PM to 3 PM
CONVENER: Knowledge Ecology International (KEI)

Knowledge Ecology International (KEI) cordially invites you to attend our side event during negotiations of the 29th Session of the Standing Committee on the Law of Patents (SCP) of the World Intellectual Property Organization (WIPO).

This panel discussion will examine the implications of Article 27.3(a) of the TRIPS Agreement on the patentability of gene- and cell-based therapies including those involving autologous T-cell immunotherapy (CAR T), CRISPR and other technologies when treatment can be described as a service or a medical procedure, rather than a product. Panelists will explore if certain cell- and gene-based treatments are, in fact, exempt from patentability when a country has an exception that mirrors Article 27.3(a) of the TRIPS Agreement. Panelists will also discuss non-patent approaches to providing incentives to invest in innovations that delink R&D costs from prices and monopolies on the medical technologies for such treatments, for example innovation inducement prize funds and market entry rewards.


Thiru Balasubramaniam, Knowledge Ecology International, Geneva Representative

James Love, Knowledge Ecology International, Director
Jayashree Watal, World Trade Organization, Counsellor, Intellectual Property Division
Dr. Els Torreele, Médecins Sans Frontières, Access Campaign, Executive Director